1. Introduction {#sec1}
===============

Inflammatory bowel disease (IBD) is a complex multifactorial disease \[[@B1]--[@B3]\]. It commonly refers to ulcerative colitis (UC) and Crohn\'s disease (CD), the two chronic conditions that involve inflammation of the intestine. IBD is common in developed countries, with up to 1 in 200 of individuals of Northern European region affected by these disease \[[@B4]\]. Patients with IBD present several clinically challenging problems for physicians. Despite recent advances in treatment, there remains a need for a safe, well-tolerated therapy with a rapid onset, and increased capacity for maintaining long-term remission \[[@B5]\].

In past decades, dozens of different animal models of IBD have been developed. These models can be broadly divided into spontaneous colitis models, inducible colitis models, genetically modified models, and adoptive transfer models \[[@B6]--[@B8]\]. Although these models do not represent the complexity of human disease, they are valuable and indispensable tools that provide a wide range of options for investigating involvement of various factors into the pathogenesis of IBD and evaluate different therapeutic options. Chemically induced murine models of intestinal inflammation are one of the most commonly used models because they are simple to induce, the onset, duration, and severity of inflammation are immediate and controllable. Both dextran sulphate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS-) induced colitis are well-established animal models of mucosal inflammation that have been used for over 2 decades in the study of IBD pathogenesis and preclinical studies \[[@B6]--[@B8]\]. The DSS-induced colitis model has some advantages when compared to other animal models of colitis. For example, an acute, chronic, or relapsing model can be produced easily by changing the concentration of administration of DSS (and cycle in rats and other strains of mice). Moreover, dysplasia that resembles the clinical course of human UC occurs frequently in the chronic phase of DSS-induced colitis. DSS-induced model for studying colitis-associated carcinogenesis has been recently reviewed by others \[[@B9], [@B10]\]. Furthermore, studies that validated DSS model by using different therapeutic agents for human IBD show that DSS-induced colitis can be used as a relevant model for the translation of mice data to human disease \[[@B11]\]. Thus, the aim of the present paper is to give a concise introduction of different factors that may be involved in the patogenesis of DSS-induced colitis and need to be taken into account when using this model. At the same time few aspects of applicability and further investigation of this model are mentioned.

2. Induction of DSS Colitis {#sec2}
===========================

First report on the use of DSS dates back in the year 1985, when Ohkusa et al. published their investigation on DSS-induced colitis in hamsters \[[@B12]\]. Thereafter, DSS colitis was induced also in mice \[[@B13]\]. Today there are numerous studies using DSS-induced colitis model to investigate pathogenesis of colitis and different factors affecting colitis. Colitis is induced by addition of DSS to drinking water. Depending on the concentration, the duration, and frequency of DSS administration, the animals may develop acute or chronic colitis or even colitis-induced dysplastic lesions. Mice show differential susceptibilities and responsiveness to DSS-induced colitis. The varying responses to DSS appear to be dependent on not only DSS (concentration, molecular weight, duration of DSS exposure, manufacturer, and batch) but also genetic (strain and substrain, gender) and microbiological (microbiological state and intestinal flora) factors of animal, which are disscussed in the present paper ([Figure 1](#fig1){ref-type="fig"}). Colitis onset and severity may vary with many of these factors. Stress can be one of them \[[@B14]\]. Differences in the DSS susceptibility do not correlate with differences in the consumption of DSS-supplemented water \[[@B15]\]. However, there is a need to monitor DSS consumption, especially when animals are exposed to different therapeutic strategies that may lower consumption of DSS (increased fluid intake or thirst) \[[@B16]\].

3. The Molecular Weight of DSS {#sec3}
==============================

DSS is sulfated polysaccharide with a highly variable molecular weight, ranging from 5 kDa to up to 1400 kDa. It was found that the molecular weight of DSS is very important factor in the induction of colitis \[[@B17]\] or colitis-induced dysplastic lesions (carcinogenicity) \[[@B18]\]. The severity of colitis \[[@B17]\] and carcinogenic activity \[[@B18]\] differs with the administration of DSS at different molecular weights (i.e., 5 kDa, 40 kDa, and 500 kDa). The most severe colitis in BALB/c mice was observed when mice were treated with DSS of 40 kDa molecular weight, while mice treated with DSS of 5 kDa developed milder form of colitis. Mice treated with DSS of 500 kDa had no lesions in the large bowel \[[@B17]\]. Similarly, carcinogenic activity in colon was induced by DSS of 54 kDa, while DSS of larger (520 kDa) or smaller (9.5 kDa) molecular weights induced no carcinogenic activity \[[@B18]\]. Examination of uptake and tissue distribution of DSS by histochemical techniques showed that failure in the induction of colitis with 500 kDa DSS is due to its high molecular weight that prevents passage of the molecule through the mucosal membrane \[[@B17]\]. Molecular weight of DSS can affect location of colitis as well. Mice treated with 40 kDa DSS developed most severe diffuse colitis in the middle and distal third of the large bowel, while mice treated with 5 kDa DSS developed relatively patchy lesions mainly in the cecum and upper colon \[[@B17]\].

3.1. Uptake and Tissue Distribution of DSS {#sec3.1}
------------------------------------------

The histochemical analyses of uptake and tissue distribution of DSS at 40 kDa molecular weight demonstrated that DSS penetrates the mucosal membrane in the intestine. One day after DSS treatment small amounts of DSS were found in macrophages in large bowel and mesenteric lymph nodes and in the liver Kupffer cells. At day 3 DSS was noticed in a few macrophages in the spleen and 7 days after the start of 5 day DSS treatment in the kidney and in a few macrophages in the small intestine. DSS was seen in the liver Kupffer cells even 8 weeks after DSS removal \[[@B19]\]. During chronic phase of DSS colitis, considerable amounts of DSS were also found in the spleen \[[@B20]\]. In other organs and tissues (for instance brain, lung, heart, thymus, stomach, and duodenum), DSS was not observed \[[@B19]\]. Major excretion routes of DSS are urine and feces. Thus, presence of DSS in the epithelial cells of the proximal renal tubules after 7 days of DSS treatment is an indication of the excretion process of absorbed DSS \[[@B19]\]. DSS is resistant to degradation by intestinal microflora or the effects of different pH conditions (4.0--7.5) and anaerobic incubation \[[@B21]\].

4. Clinical and Histological Features of DSS-Induced Colitis {#sec4}
============================================================

Clinical and histopathological features of DSS-colitis reflect those seen in human IBD. Acute colitis is usually induced by continuous administration of 2--5% DSS for short period (4--9 days). Chronic colitis may be induced by continuous treatment of low concentrations of DSS or cyclical administration of DSS. For instance, 4 cycles of DSS treatment for 7 days followed by 10 days of water ([Table 4](#tab4){ref-type="table"}). Clinical manifestation of DSS colitis in acute phase may include weight loss, diarrhea, occult blood in stools, piloerection, anaemia, and eventually death. However, clinical manifestations in chronic phase of colitis usually do not reflect severity of inflammation or histologic features found in large bowel.

Histological changes in DSS-induced colitis can be classified as acute (early) and chronic (advanced). Typical histological changes of acute DSS-colitis are mucin depletion, epithelial degeneration, and necrosis leading to disappearance of epithelial cells ([Figure 2(a)](#fig2){ref-type="fig"}). The latter is accompanied by neutrophils infiltration of lamina propria and submucosa, cryptitis, crypt abscesses (Figures [3(b)](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), and phlegmonous inflammation in mucosa and submucosa ([Figure 2(b)](#fig2){ref-type="fig"}). Usually also shallow erosions appear ([Figure 2(b)](#fig2){ref-type="fig"}). Rarely there is a vacuolar hydropic degeneration of cells ([Figure 3(a)](#fig3){ref-type="fig"}). Transepithelial migration of neutrophils into mucosal epithelium is termed cryptitis. Migration of numerous neutrophils through mucosal epithelium into crypt lumen results in the formation of crypt abscess. Cryptitis and crypt abscesses are common histological feature of human IBD but rarely reported in DSS-induced colitis using haematoxylin-eosin staining method \[[@B22]\]. In contrast, we found cryptitis and crypt abscesses in half of DSS-treated C57BL/6JOlaHsd mice, while in BALB/cAnNHsd mice cryptitis was rarely observed (unpublished data). However, we used Kreyberg-Jareg trichrom staining method that differentially stains acid mucopolysaccharides blue and thus contributes to better distinction between normal and aberrant mucosa. Interestingly, the presence of neutrophils in the epithelial lining of colon mucosa (cryptitis) and in the lumen of crypts (crypt abscess) was reported in DSS-treated C57BL/6OlaHsd mice when investigators used immunofluorescent staining against neutrophils \[[@B23]\].

Chronic changes appear few weeks after DSS application. They consist of mononuclear leucocytes infiltration, crypt architectural disarray ([Figure 5(a)](#fig5){ref-type="fig"}), increasing the distance (widening of the gap) between crypt bases and muscularis mucosa, deep mucosal lymphocytosis ([Figure 4(a)](#fig4){ref-type="fig"}), and transmural inflammation ([Figure 6](#fig6){ref-type="fig"}). It is widely believed that transmural inflammation is infrequent feature of DSS-induced colitis. In contrast, we observed transmural inflammation in C57BL/6JOlaHsd mice as well as in BALB/cAnNHsd mice, consonant with observation by Melgar et al. \[[@B22]\]. Moreover, in chronic colitis of C57BL/6JOlaHsd mice we even observed transmural inflammation with lymphoid follicles ([Figure 6(b)](#fig6){ref-type="fig"}), which is histological feature of Crohn\'s disease and was until now not observed in DSS colitis model.

Rarely reported characteristic change is also reepithelisation of rectal and distal colonic erosions by squamous epithelium that evidently originates from anal squamous mucosa ([Figure 7](#fig7){ref-type="fig"}). In some slides islands of squamous epithelium are found surrounded by colonic mucosa proximally and distally, but in most cases with deeper sections there appeared a continuity of squamous epithelium distally, suggesting an irregular shape of a squamous cell regenerate. Focally sometimes there is a moderate epithelial regeneratory atypia simulating dysplasia ([Figure 5(b)](#fig5){ref-type="fig"}). Most frequently it is found at the edge of chronic erosions.

We observed reepithelisation of distal part of colon as early as day 5 of DSS treatment in C57BL/6JOlaHsd but not in BALB/cAnNHsd mice. According to our experience reepithelisation of distal colon with squamous epithelium is frequent observation in C57BL/6JOlaHsd mice 1--4 weeks after DSS removal. The distance of reepithelisation with squamous epithelium that we measured under microscope ranged from 0.5--6.5 mm of colon length.

Histological changes seen in mouse DSS-induced colitis are the features of IBD in man, some of them of ulcerative colitis (regular rectal localization) and some of Crohn\'s disease (transmural inflammation with disseminated lymphoid follicles, focal lesions) \[[@B24], [@B25]\].

Besides all in [Figure 1](#fig1){ref-type="fig"}, mentioned factors that affect features of DSS-induced colitis preparation of tissues for histological examination may also be one of the reasons for discrepancy among studies. According to our experience as well as recommendation of other investigators \[[@B15]\] longitudinal sections as well as at least few sections of the same slide at intermediate distance of not less than 0.1 mm may better reflect the actual damage of DSS colitis than cross sections because of the patchy nature of DSS-induced lesions. In addition, the choice of staining method may also affect histological observations. For instance, cryptitis, crypt abscesses as well as squamous reepithelisation are easier to diagnose in sections stained with Kreyberg-Jareg method than hematoxylin-eosin method.

5. The Role of Intestinal Flora in the Pathogenesis of DSS-Induced Colitis {#sec5}
==========================================================================

Intestinal microflora and their products have been implicated in the pathogenesis of human IBD \[[@B2], [@B26]--[@B28]\] and in several animal models \[[@B29]\]. The importance of the intestinal flora is directly supported by studies of some murine models where colitis is not observed when they are maintained in a gnotobiotic state but rapidly emerges when they are reconstituted with bacteria that are considered normal constituents of luminal flora (explained in detail by Nell et al. \[[@B29]\]). It has been demonstrated that intestinal flora is implicated in the pathogenesis of DSS colitis in mice as well. First who suggested contribution of colonic bacteria or their products in the development of colitis in this model were Okayasu et al. \[[@B13]\]. They observed increased numbers of Enterobacteriaceae, Bacteroidaceae, and Clostridium spp. in the colons of mice affected by DSS colitis \[[@B13]\]. Another suggestion in this direction was given by Hans et al. \[[@B30]\], who reported that treatment with antibiotics reduced infiltration of granulocytes in the mucosa and improved histological signs of DSS colitis in acute phase \[[@B30]\]. The role of commensal bacteria and innate immunity in the development of intestinal inflammation has been further demonstrated by Hudcovic et al. \[[@B31]\]. When DSS-treated immunocompetent BALB/c and immunodeficient SCID mice (lacking T and B lymphocytes) were maintained under conventional conditions, both strains developed substantial changes in the colon mucosa. BALB/c mice showed complete loss of the surface epithelium and severe infiltration of inflammatory cells. To evaluate susceptibility to DSS colitis in gnotobiotic conditions BALB/c and SCID mice were transferred into isolators for germ-free rearing by special gnotobiological techniques. Interestingly, BALB/c and SCID mice reared in germ-free conditions (lacking any intestinal microflora) developed only minor signs of mucosal inflammation after DSS treatment \[[@B31]\]. This finding indicates that the presence of microflora facilitates the inflammation in DSS-induced colitis. Similar findings were observed by Kitajima et al. \[[@B32]\]. They used IQI/Jic mice maintained in germ-free conditions and their littermates that were conventionalized with feces obtained from SPF BALB/c mice three weeks before DSS administration. Histopathological findings revealed that IQI/Jic mice under germ-free conditions had no lesions indicative of colitis in the large intestine 3 days after 5% DSS treatment, while IQI/Jic mice in conventional conditions developed focal erosions in the large bowel, mostly in the cecum and proximal colon. Interestingly, when both groups of mice were treated with 1% DSS for 14 days, mice under germ-free conditions developed slight inflammatory cell infiltration and edema in the lamina propria of the cecum and proximal colon and sever ulcerations, hemorrhages with frequent thrombi, and slight inflammatory cell infiltration in the distal colon. In the large bowel of IQI/Jic mice in conventional conditions only focal lesions of slight inflammatory cells infiltration and edema in mucosa along the whole large bowel were observed \[[@B32]\]. These findings demonstrate firstly that mucosal destruction caused by DSS occurs without the involvement of intestinal microflora and secondly that intestinal microflora may play an important modifying role in the susceptibility and responsiveness to DSS-induced damage of epithelial cells. The role of intestinal microflora in DSS-induced colitis is further investigated in mice deficient for different toll-like receptors (TLR), which function as sensors of microbial infection and are critical for the initiation of inflammatory and immune defence responses \[[@B33]\].

6. The Role of Genetic Factors in the Pathogenesis of DSS-Induced Colitis {#sec6}
=========================================================================

Similar to IBD in humans \[[@B3]\], genetic factors play important role in DSS-induced colitis. Differences in susceptibility and responsiveness to DSS-induced colitis among inbred strains and substrains of mice have been identified. A quantitative histological analysis of DSS-induced colitis in nine mouse strains using a standardized protocol (3.5% DSS of 36--45 kDa molecular weight for 5 days) demonstrated major differences in DSS responsiveness among strains \[[@B15]\]. C3H/HeJ, NOD/Ltj, and NOD-scid inbred strains are very susceptible to DSS-induced lesions, which develop in severe form mostly in the cecum. 129/SvPas and DBA/2J inbred mice are less susceptible to DSS-induced lesions and show various degrees of susceptibility to DSS, depending upon anatomical site as schematically demonstrated in the [Table 1](#tab1){ref-type="table"}. Interestingly, severity of DSS-induced lesions in most inbred strains increased from proximal to the distal colon. A greater susceptibility to DSS-induced colonic but not cecal lesions was observed in male mice \[[@B15]\].

Stevceva et al. \[[@B34]\] demonstrated that C3H mice are more susceptible to DSS colitis than CBA/H and BALB/c. C3H mice developed severe colitis with severe inflammatory response predominantly involving ascending (proximal) colon and cecum, while CBA/H and BALB/c mice developed severe colitis mostly in distal colon. BALB/c mice, which are frequently used strain in DSS-colitis, are also less susceptible to DSS as IQI/Jic \[[@B32]\] or C57BL/6 \[[@B22]\]. The differences in the susceptibility to DSS-induced lesions were either due to genetic differences in the ability of the mucosa to withstand inflammatory damage, differences in the ability to limit the inflammatory response, or both. Melgar et al. \[[@B22]\] demonstrated differences in the progression of DSS colitis between two commonly used strains. After DSS withdrawal (one cycle), BALB/c mice recovered of DSS colitis, while in C57BL/6 mice colitis progressed into chronic phase \[[@B22]\]. The genetic factors contributing to DSS susceptibility in mice are unknown. Interestingly, some strains of mice are able to limit and eliminate DSS-induced inflammatory response in colon, while inflammatory process in C57BL/6 mice can not be repared but progresses into chronic form of colitis \[[@B22]\]. This indicates that genetic factors are importantly involved into regulations of inflammatory response, which is of great interest for further research.

7. Pathogenesis of DSS-Induced Colitis {#sec7}
======================================

It is widely accepted that DSS is toxic to colonic epithelial cells and causes defects in the epithelial barrier integrity, whereby increasing the colonic mucosal permeability to allow permeation of large molecules such as DSS. The mechanism of how DSS passes through the mucosal epithelial cells (transcellularly or paracellularly mediated via tight junctions) remains uncertain. First changes related to DSS were observed after 1 day of DSS treatment. These changes were loss of one of the components of tight junction complex \[[@B35], [@B36]\] zonula occludens-1 (ZO-1) \[[@B37]\] and significantly increased expression of proinflammatory cytokines (TNF-*α*, IL-1*β*, IFN-*γ*, IL-10, and IL-12) in the colon \[[@B38]\]. By day 3 of DSS treatment significant increase in permeability to Evan\'s blue was observed \[[@B37]\]. At this time first histological changes in the colonic mucosa in the form of basal crypts loss and increased inflammatory cells infiltration can be seen. In acute phase of DSS colitis the impairment of epithelial barrier function is associated with loss and redistribution of the tight junction proteins such as occludin, ZO-1 \[[@B37]\], claudin-1, -3, -4, and -5 and an increased epithelial apoptotic ratio \[[@B39]\]. Altered expression of tight junction proteins and increased epithelial apoptosis were reported also in human IBD. It was proposed that imbalance between apoptosis and proliferation causes relevant leaks in the epithelial barrier. This is supported by the finding that both increased apoptosis and decreased proliferation of the epithelium take place in the acute phase of DSS colitis \[[@B40]\]. The single layered intestinal epithelium is a physical and immunological barrier that prevents direct contact of the intestinal mucosa with the luminal microbiota.

As evidenced by the amelioration of inflammation in germ-free animals and in mice treated with antibiotics \[[@B27], [@B30], [@B31]\], DSS-induced breakdown of mucosal epithelial barrier function allows the entry of luminal antigens and microorganisms into the mucosa resulting in overwhelming inflammatory response.

Microarray analysis of the gene expression revealed that 173 genes were differentially and significantly expressed in the colon of DSS-treated mice by a factor of two or more when compared to control mice. Fifteen were previously associated with IBD in humans (shown in [Table 2](#tab2){ref-type="table"}) \[[@B41]\]. Intestinal Na^+^-related transporters/channels and their regulatory proteins (NHE1,3, *β*-ENaC, and NHERF1,2) have been found to be downregulated in mouse colon in acute phase of DSS colitis and in mucosal biopsies from IBD patients (UC or CD) in active phase of disease \[[@B42]\].

7.1. Inflammatory Response and Mediators Involved in the Pathogenesis of DSS Colitis {#sec7.1}
------------------------------------------------------------------------------------

Numerous inflammatory mediators have been implicated in the pathogenesis of human IBD. These include cytokines, eicosanoids, reactive oxygen species, nitric oxide, and complement system activation products \[[@B43]--[@B46]\]. Similarly, DSS-induced colitis is associated with the upregulation of different cytokines, chemokines, nitric oxide \[[@B47], [@B48]\], and inducible nitric oxide synthase (iNOS) \[[@B49]\]. Changes in production of inflammatory mediators in DSS-treated mice were investigated during different phases of colitis, in the serum and/or colon and by different methods (shown in [Table 3](#tab3){ref-type="table"}). Increased expression of different inflammatory mediators (TNF-*α*, IL-1*β*, IFN-*γ*, IL-10, and IL-12) was observed as early as the first day of DSS treatment \[[@B38]\]. The production of these inflammatory mediators increased progressively during DSS treatment. Different profile of inflammatory mediators in acute and chronic phase of DSS colitis was demonstrated. Acute inflammation in DSS colitis converts to a predominant Th2-mediated inflammatory response in the chronic state (lower levels of TNF-*α*, IL-17, and KC and elevated levels of IL-6, IFN-*γ*, and IL-4, IL-10) \[[@B50]\]. Progressive upregulation in the transcripts for Th1 cytokines (IL-12, IFN-*γ*, IL-1, and TNF-*α*) was observed with increasing dosage of DSS \[[@B51]\]. Different cytokine profile in chronic phase of DSS colitis was found between BALB/c and C57BL/6J mice, which reflected the severity of inflammation or infiltration of inflammatory cells in the colon found histologically \[[@B22]\].

These inflammatory mediators not only play a role in the pathogenesis of DSS-induced colitis but are important as intervention targets against colitis as excellently described by Kawada et al. \[[@B52]\]. Cytokine profile in DSS colitis correlates with clinical and histological parameters as well as barrier properties. Different expression depending on strain and phase of colitis provides this model as a useful tool to dissect the role of these cytokines in the induction of inflammation and recovery from it.

Recently comprehensive study of mucosal and systemic immune responses in C57BL/6OlaHsd mice exposed to 3% DSS for 6 days has been performed using immunofluorescent staining and flow cytometry analyses. It has been shown that adaptive immune responses in this mouse strain are induced during both acute and chronic phase of colitis in all organs tested, that are, colon, spleen, and mesenteric lymph nodes as early as day 1 of DSS treatment until the end (i.e., day 25) \[[@B23]\]. Interplay of neutrophils, dendritic cells, macrophages, and T and B cells among spleen, mesenteric lymph nodes, and colon in DSS-treated C57BL/6OlaHsd mice in temporal fashion is schematically represented in [Figure 8](#fig8){ref-type="fig"}.

8. Geneticaly Modified Mice and DSS Treatment {#sec8}
=============================================

DSS-induced colitis is nowadays frequently used in genetically engineered mice (GEM), to study basic immunologic mechanisms of IBD and to elucidate the role of particular deleted (^−/−^) or inserted (Tg) gene in the pathogenesis of the colitis.

Toll-like receptors (TLR) are critical receptors and signal transducers for structurally conserved pathogen-associated molecular patterns of bacterial cell components (such as lipopolysaccharide) that provoke innate immune responses by stimulating macrophages/dendritic cells to produce proinflammatory cytokines. It has been shown that mice deficient for different TLR (TLR2, TLR4) or other molecules, which are implicated in signaling via TLR such as myeloid differential protein (MyD88), are very susceptible to DSS colitis, indicating important protective role of these molecules in colitis \[[@B33], [@B55]--[@B53]\]. Overproduction of IL-18 or deletion of TNF-*α* has been shown to exacerbate DSS colitis \[[@B49], [@B56]\]. On the other hand mice deficient for IL-15 showed reduced susceptibility to DSS colitis \[[@B57]\]. Mice deficit for IL-12 developed mild DSS colitis, while mice deficit for IL-18 developed severe colitis associated with high lethality \[[@B58]\]. Deletion of suppressor of cytokine signaling-1 (SOCS-1), which is a negative feedback molecule for cytokine signaling, increased susceptibility to DSS colitis, suggesting that SOCS-1 plays preventive role in the development of DSS-induced colitis in mice by inhibiting IFN-*γ*/STAT1 signaling \[[@B59]\]. Interferon regulatory factor-1 (IRF-1) is a transcription factor stimulated by IFN-*γ* and TNF-*α* that binds to the promoter region of inflammation-related genes, such as IFN-*α*, IFN-*β*, and iNOS. It is expressed in lymphocytes, monocytes, and a wide variety of other cell types, including enterocytes. Mice lacking IRF-1 transcription factor developed significantly increased DSS-induced colonic dysplasia \[[@B60]\]. Tryptophan hydroxylase-1 (TPH1) catalyzes the rate-limiting step in the synthesis of 5-hydroxytryptamine (5-HT) from tryptophan. It is an important enteric mucosal signaling molecule influencing gut physiology (motor and secretory function) following inflammation and is considered important in maintaining intestinal homeostasis. However, mice lacking TPH1 had significantly reduced susceptibility to DSS colitis \[[@B61]\].

Taken together, GEM treated with DSS are valuable model to test different molecules, which are involved in the mediation of inflammation such as cytokines (IL-12, IL-15, IL-18, TNF-*α*), nitric oxides (iNOS, eNOS, and nNOS), complement system activation products or other molecules involved in signaling of inflammation (SOCS-1, IRF-1), to further identify bacterial factors involved in maintaining intestinal homeostasis (TLR, MyD88), to investigate the role of particular factor when totally deleted or deleted only in particular types of cells such as intestinal, (PPAR*γ*^ΔIEpC^; Vhl^ΔF/F^; Hif-1*α*^ΔF/F^; Arnt^ΔF/F^) or CD4+ T cells (PPAR*γ*^ΔCD4+^) and to test therapeutic interventions based upon inhibition of particular gene expression strategies (TPH1, APN, and MRP1). In the [Table 4](#tab4){ref-type="table"} susceptibility to DSS-induced colitis in mice deficient for a particular gene is shown. Mouse background, gender, microbiological state, molecular weight of DSS, and DSS treatment, factors that importantly affect DSS colitis and need to be taken into account in designing investigation or evaluating results, are also stated.

9. Conclusion {#sec9}
=============

DSS-induced model is simple to induce and not expensive, which makes it one of the most commonly used model of IBD to study various aspects of IBD such as pathogenesis, genetic predisposition to IBD, immune mechanisms, and role of microflora in the pathogenesis of IBD as well as bowel malignancy secondary to IBD. As demonstrated above, various factors may affect susceptibility to DSS and modify results. Representative examples of how important can be all mentioned details are studies where two groups of researchers investigated the role of adiponectine in DSS colitis. Both groups used in their studies the same mice model (mice with APN deletion) exposed to DSS treatment. They observed quite opposite results \[[@B67], [@B68]\]. It is thus advisable to state and describe all details and conditions that may affect the DSS susceptibility.

This work was in part supported by ARRS (Slovenian Research Agency, Program P3-0054).

![Schematic simplified representation of various factors that can influence the susceptibility, onset, severity, and responsiveness to DSS-induced colitis.](JBB2012-718617.001){#fig1}

![(a) Disappearance of crypts. (b) Erosion and phlegmonous inflammation of mucosa and submucosa. Kreyberg trichrom stain (acid mucopolysaccharides are stained blue). C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 5 days followed by drinking water for 7 days.](JBB2012-718617.002){#fig2}

![(a) Vacuolar hydropic degeneration of cells. (b) Epithelial necrosis, cryptitis, and crypt abscesses. Kreyberg trichrom stain (acid mucopolysaccharides are stained blue). C57BL/6JOlaHsd female mice exposed to 3% DSS solution for 5 days followed by drinking water for 21 days.](JBB2012-718617.003){#fig3}

![Arrows denote crypt abscesses (neutrophils) in the lumen of crypts. Kreyberg trichrom stain (acid mucopolysaccharides are stained blue). C57BL/6JOlaHsd male mice are exposed to 3% DSS solution for 5 days followed by drinking water for (a) 7 days and (b) 28 days.](JBB2012-718617.004){#fig4}

![(a) Mononuclear leucocytes infiltration, crypt architectural disarray, and deep mucosal lymphocytosis. (b) Focally there is a moderate epithelial regeneratory atypia simulating dysplasia (arrow). Kreyberg trichrom stain (acid mucopolysaccharides are stained blue). C57BL/6JOlaHsd male mice are exposed to 3% DSS solution for 5 days followed by drinking water for 28 days.](JBB2012-718617.005){#fig5}

![(a) Focal transmural chronic colitis (skip lesion). C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 5 days followed by drinking water for 28 days. (b) Transmural inflammation with lymphoid follicles in subserosa (arrows) and chronic erosion. C57BL/6JOlaHsd female mice are exposed to 3% DSS solution for 9 days followed by drinking water for 28 days. Kreyberg trichrom stain (acid mucopolysaccharides are stained blue).](JBB2012-718617.006){#fig6}

![(a) and (b) reepithelisation of rectal and distal colonic erosion by squamous epithelium (arrows). C57BL/6JOlaHsd male mice are exposed to 3% DSS solution for 5 days followed by drinking water for 7 days. Kreyberg trichrom stain (acid mucopolysaccharides are stained blue).](JBB2012-718617.007){#fig7}

![Schematic representation of mucosal (colon) and systemic (spleen, MLN) immune responses in C57BL/6OlaHsd mice exposed to 3% DSS for 6 days followed by water for 19 days. Measurements were made on day 0, 1, 3, 5, 8, 12, and 25 as denoted by numbers. Schematic representation is based on results obtained by Hall et al. \[[@B23]\]. MLN: mesenteric lymph nodes, N: neutrophils, M: macrophages, DC: dendritic cells, T: T cells, B: B cells.](JBB2012-718617.008){#fig8}

###### 

Susceptibility to DSS-induced colitis among inbred strains (adapted from \[[@B15]\]).

               Cecum   Proximal colon   Middle colon   Distal colon
  ------------ ------- ---------------- -------------- --------------
  DBA/2J       BC      ---              A              A
  NON/LtJ      AB      ---              A              A
  NON.H2^g7^   AB      ---              AB             AB
  129/SvPas    A       ---              AB             B
  NOD-scid     D       A                AB             BC
  C57BL/6J     BC      A                B              BC
  C3H/HeJ      D       A                AB             C
  NOD/LtJ      CD      ---              B              BC
  C3H/HeJBir   D       A                AB             C

Strains that do not share the same letter in a column have significat differences in histological score for particular part of the colon after DSS administration. Letter A denotes the lowest histological score, while D denotes the highest histological score observed among the strains. --- denotes no changes found in the colon (normal mucosa).

###### 

Differentially expressed genes in acute phase of DSS colitis that had been previously associated with human IBD \[[@B41]\].

  Gene          Name               Expression   Gene      Name                                                    Expression
  ------------- ------------------ ------------ ---------------------------------------------------------------- -------------
  *Cytokine*                                    *Genes involved in tissue remodeling*                            
  * IL-6*       Interleukine-6     ↑ 2.6        * Mmp3*       Stromelysin 1                                       ↑ 22.5
  * IL-16*      Interleukine-16    ↓ 2.7        * Mmp14*    Membrane type 1 MMP                                   ↑ 2.1
  * IL-22*      Interleukine-22    ↑ 2.4        * Timp1*    Tissue inhibitor of metalloproteinase 1               ↑ 3.6
                                                                                                                 
  *Chemokine*                                   *Regenerating islet-derived genes*                               
  * CCL2*       JE (human:MCP-1)   ↑ 1.8        * Reg3γ*    Regenerating islet-derived 3*γ*                       ↑ 14.0
  * CCL3*       MIP-1*α*           ↑ 3.3        * Pap*     Pancreatitis-associated protein                        ↑ 79.1
  * CCL11*      Eotaxin            ↑ 3.3        * S-100a9*    S-100 calcium-binding protein A9 (calgranulin B)    ↑ 14.0
  * CXCL1*      KC (hu: GRO*α*)    ↑ 2.9        *Prostaglandin metabolism*                                       
  * CXCL5*      LIX (hu: ENA-78)   ↑ 6.6        * Ptgs2*     Prostaglandin-endoperoxidase synthase 2 (COX-2)      ↑ 4.1

Colitis was induced in 8 wk female BALB/c mice that received 3% DSS for 7 days and were sacrificed on day 7. ↑: significantly increased expression by denoted factor, ↓: significantly decreased expression by denoted factor.

###### 

Profile of inflammatory mediators in different phases of DSS-induced colitis in mice.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tissue/method                Analytes measured                                                                                                 acute DSS colitis                 chronic DSS colitis                                       Mouse strain   ref.
  ---------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------------------- -------------- ------------
                                                                                                                                                 *7 days of DSS treatment*                                                                                  

                                                                                                                                                                                                                                                            

  Colon/RT PCR                 IL-1, IL-4, IL-10, IL-12, IFN*γ*, TNF*α*                                                                          ↑ IL-1, IL-10, IL-12,\            ---                                                       BALB/c         \[[@B51]\]
                                                                                                                                                 ↑ IFN-*γ*, TNF*α*                                                                                          

                                                                                                                                                                                                                                                            

                                                                                                                                                 *5 days of DSS treatment*         *5 days of DSS followed by 28 days of water*                             

                                                                                                                                                                                                                                                            

  Colon/ELISA, MSI             IL-1*α*, IL-1*β*, IL-12 p40, IL-12 p70, IL-17, IL-6, G-CSF, IL-18                                                 ↑ IL-1*α*, IL-1*β*, IL-12 p40,\   ↑ IL-1*α*, IL-1*β*, IL-12 p40,\                           C57BL/6J       \[[@B22]\]
                                                                                                                                                 ↑ IL-12 p70, IL-17, IL-6,\        ↑ IL-12 p70, IL-17, IL-6,\                                               
                                                                                                                                                 ↑ G-CSF                           ↑ G-CSF                                                                  

  ↑ IL-1*α*, IL-1*β*, IL-6,\   ↑ IL-12 p40                                                                                                       BALB/c                            \[[@B22]\]                                                               
  ↑ IL-18, G-CSF                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                            

                                                                                                                                                 *5 days of DSS treatment*         *5 days of DSS followed by 7 days of water*                              

                                                                                                                                                                                                                                                            

  Colon/RT PCR                 TNF-*α*, IL-1*β*, IL-6, IL-10, IL-12, IFN-*γ*, KC, MIP-2                                                          ↑ TNF-*α*, IL-1*β*, IL-6,\        ↑ TNF-*α*, IL-1*β*, IL-6, IL-10,\                         C57BL/6J       \[[@B38]\]
                                                                                                                                                 ↑ IL-10, IL-12, IFN-*γ*,\         ↑ IL-12, IFN-*γ*, KC, MIP-2                                              
                                                                                                                                                 ↑ KC, MIP-2                                                                                                

                                                                                                                                                                                                                                                            

                                                                                                                                                 *7 days of DSS treatment*         *4 cycles of 7days of DSS followed by 10 days of water*                  

                                                                                                                                                                                                                                                            

  Serum/MSI                    IL-1*β*, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IFN-*γ*, TNF-*α*, GM-CSF, IP-10, KC, MCP-1, MIG, MIP-1*α*   ↑ IL-6, IL-17, TNF-*α*, KC        ↑ IL-6, IFN-*γ*, IL-4, IL-10                                             \[[@B50]\]

  Colon/Western                IL-6, IL-12, IL-23, IL-17, IFN-*γ*                                                                                ↑ IL-6, IFN-*γ*, IL-17            ↑ IL-6                                                    C57BL/6J       \[[@B50]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RT PCR: real-time PCR; MSI: multiplex sandwich immunoassay; IFN-*γ*: interferone gama; IL: interleukine; GM-CSF: granulocyte-macrophage colony-stimulating factor; IP-10: interferon-inducible protein; KC: keratinocyte-derived chemokine; MCP-1: monocyte chemoattractant protein; MIG: monokine induced by IFN-*γ*; MIP-1*α*: macrophage inflammatory protein; TNF-*α*: tumor necrosis factor alpha.

###### 

Genetically engineered mouse models in the pathogenesis of DSS colitis.

  GEM model        Background (breeder)   Age gender *N*   MS    MW of DSS    DSS treatment       End         S    Ref
  ---------------- ---------------------- ---------------- ----- ------------ ------------------- ----------- ---- --------------------
  TLR2^−/−^                                                                                                        
  TLR4^−/−^                                                                                                        
  TLR2/4^−/−^      C57BL/10ScSn           *N* = 10--12     nr    40 kDa       3.5% for 7 days     Day 8       ↑    \[[@B55]\]
                                                                                                                   
                                          5--8 wks                                                                 
  TLR4^−/−^        C57BL/6J               Male, female                        2.5% for 5 days     Day 5            
  MyD88^−/−^       (Jax)                  *N* = 5-6        nr    36--50 kDa   2.5% for 5/7 days   Day 12/14   ↑    \[[@B54]\]
                                                                                                                   
  TLR2^−/−^                                                                                                        
  TLR4^−/−^        F2                                                                                              
  MyD88^−/−^       129/SvJ × C57BL/6                       SPF   40 kDa       2% for 7 days       Day 0--28   ↑    \[[@B33]\]
                                                                                                                   
                                          8 wks                                                                    
                                          Male                                1.2% for 8 days                      
  MyD88^−/−^       nr                     *N* = 10         SPF   50 kDa       2.5% for 8 days     Day 8       ↑    \[[@B53]\]
                                                                                                                   
                                          10 wks                                                                   
                   C57BL/6                Male                                                                     \[[@B56], [@B62]\]
  IL-18^Tg^        (nr)                   *N* = 20         SPF   50 kDa       2% for 8 days       Day 12      ↑    
                                                                                                                   
                                                                              3 cycles of                          
                   C57BL/6                7--9 wks                            2% for 5 days +     Day 5            
  IL-15^−/−^       (Taconic)              *N* = 11         nr    36--50 kDa   5 days of water     Day 25      ↓    \[[@B57]\]
                                                                                                                   
                   C57BL/6J               Male, female                                                             
  TNF-*α*^−/−^     (Shimizu, Japan)       *N* = 15         nr    8 kDa        4.5% for 7 days     Day 7       ↑    \[[@B49]\]
                                                                                                                   
                                          8--10 wks                                                                
                                          Male                                                                     
  MRP1^−/−^        FVB                    *N* = 8          SC    40 kDa       3% for 7days        Day 7       ↑    \[[@B63]\]
                                                                                                                   
                   C57BL/6                8-9 wks                                                 Day 4, 7         
  Mtgr1^−/−^       (nr)                   Male, female     nr    40--50 kDa   3% for 4days        Wk 6, 10    ↑    \[[@B64]\]
                                                                                                                   
                                          7-8 wks                                                                  
                   C57BL/6                Male, female                        3% for 5 days                        
  SOCS-1^+/−^      (nr)                   *N* = 14         SPF   36--50 kDa   (4% for 7 days)     Day 14      ↑    \[[@B59]\]
                                                                                                                   
                                                                              5 cycles of                          
                   C57BL/6J               8--12 wk                            2% for 7 days +                      
  IRF-1^−/−^       (Jax)                  *N* = 15         nr    40 kDa       7 days of water     Wk 10       ↑    \[[@B60]\]
                                                                                                                   
                                          8--10 wk                                                                 
                                          Female                                                                   
  PPAR*γ*^ΔIEpC^   nr                     *N* = 20         nr    35--40 kDa   2.5% for 7 days     Day 7       ↑    \[[@B65]\]
                                                                                                                   
                   C57BL/6J                                                                                        
  PPAR*γ*^ΔCD4+^   (nr)                   *N* = 34         nr    36--44 kDa   2.5% for 7 days     Day 0,2,7   ↑    \[[@B66]\]
                                                                                                                   
                   C57BL/6                                                                                         
  TPH1^−/−^        (Taconic)              *N* = 10         nr    40 kDa       5% for 5 days       Day 5       ↓    \[[@B61]\]
                                                                                                                   
  Bk2R^−/−^        C57BL/6                8--12 wk                                                            ns   
  C3^−/−^          (Jax)                  *N* = 8          nr    36--40 kDa   3% for 10 days      Day 10      ↓    \[[@B43]\]
                                                                                                                   
                   C57BL/6                Male, female                                                             
  iNOS^−/−^        (Jax)                  *N* = 5          nr    40 kDa       2.5% for 9 days     Day 3,9     ↓    \[[@B47], [@B48]\]
                                                                                                                   
  eNOS^−/−^                                                                                                   ↓    
  nNOS^−/−^        129/Sv × C57BL/6       Male, female                                                        ↑    
  e/nNOS^−/−^      (Jax)                  *N* = 5          nr    40 kDa       2.5% for 9 days     Day 3,9     ns   \[[@B47]\]
                                                                                                                   
                                          5--10 wks                                                                
                   C57BL/6                Female                                                                   
  APN^−/−^         (nr)                   *N* = 5--7       nr    40 kDa       2% for 5 days       Day 5,10    ↓    \[[@B67]\]
                                                                                                                   
                                          8--10 wks                                                                
                   C57BL/6J               Male                                                                     
  APN^−/−^         (Clea Japan)           *N* = 11         SPF   36--50 kDa   0.5% for 15 days    Day 15      ↑    \[[@B68]\]
                                                                                                                   
  Vhl^ΔF/F^                                                                                       Day 5       ↑    
  Hif-1*α*^ΔF/F^                          6--8 wk                             2.5% or 5% for      1 year      ns   
  Arnt^ΔF/F^       nr                     nr               nr    35--40 kDa   5 days                          ns   \[[@B69]\]

GEM: genetically engineered mice, *N*: number of mice pre group, MS: microbiological state, MW: molecular weight, S: susceptibility to DSS in comparison to wild-type mice (mice of the same strain without deletion), ↓: significantly lower, SFP: specific pathogen-free conditions, SC: standard conditions, ns: nonsignificant, nr: not reported, ↑: significantly higher, wk: week, TLR: toll-like receptor, MyD88: myeloid differential protein, IL: interleukine, MRP: multi drug resistant protein, Mtgr: myeloid translocation gene related-1, SOCS: suppressor of cytokine signaling, IRF: Interferon regulatory factor, PPAR: peroxisome proliferator-activated receptor, TPH: tryptophan hydroxylase, Bk2R: bradykinin type 2 receptor, C3: complement, APN: adiponectine, Vhl: von Hippel-Lindau tumor suppressor protein, Hif: hypoxia-inducible factor, Arnt: aryl hydrocarbon nuclear translocator.
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